Prescribing information

 

   

Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.

Convenient dosing schedule that delivers all the benefits of Cosentyx

Adult PsO

The recommended dose for PsO is 300 mg with initial dosing at Weeks 0, 1, 2, 3, and 4, followed by monthly maintenance dosing.*1

Dosing table. The recommended dose for psoriasis is 300 mg with initial dosing at Weeks 0, 1, 2, 3, and 4, followed by monthly maintenance dosing.

*Individual patient dosing may vary - please consult the Prescribing Information for full details.

Paediatric PsO

The recommended dose is based on body weight with initial dosing at Weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing.1

Each 75 mg dose is given as one subcutaneous injection of 75 mg. Each 150 mg dose is given as one subcutaneous injection of 150 mg. Each 300 mg dose is given as one subcutaneous injection of 300 mg.1

Dosing table. The recommended dose for psoriasis is 75 mg with initial dosing at Weeks 0, 1, 2, 3, and 4, followed by monthly maintenance dosing.

The 150 mg and 300 mg solution for injection in pre-filled syringe and in pre-filled pen are not indicated for administration to paediatric patients with a weight <50 kg. Cosentyx may be available in other strengths and/or presentations depending on the individual treatment needs.1

Dosing table. The recommended dose for psoriasis is 150 mg with initial dosing at Weeks 0, 1, 2, 3, and 4, followed by monthly maintenance dosing.

*May be increased to 300 mg. Some patients may derive additional benefit from the higher dose. Each 300 mg dose is given as one subcutaneous injection of 300 mg or as two subcutaneous injections of 150 mg.1

The 150 mg and 300 mg solution for injection in pre-filled syringe and in pre-filled pen are not indicated for administration to paediatric patients with a weight <50 kg. Cosentyx may be available in other strengths and/or presentations depending on the individual treatment needs.1

 

Supporting your Cosentyx patients virtually

 

Icon of a file inside of a web browser window and a magnifying glass

We have now digitised our patient packs, leaflets, dosing charts and more. Make sure you can continue to support your Cosentyx patients virtually by exploring our patient resources.

 

Show more

CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; SC, subcutaneous.

Reference

  1. Cosentyx Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | February 2022 | 187462
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]